Ocumension Therapeutics Announces Clinical Trial Authorization for Initiating A Phase III Clinical Trial of Ot-101-S
conditions has long been a technical barrier towards commercialization. Studies show that, as compared to the high-concentration (0.5%-1%) atropine sulfate eye drop which has frequently reported adverse events including photophobia and blurred vision, low-concentration atropine sulfate eye drop has demonstrated good tolerability, safety and efficacy results. As compared to OT-101, which is designed to contain two chambers of atropine sulfate lyophilized powder and solvent for each dosage unit, OT-101-S is designed to contain two chambers of atropine sulfate concentrated solution and diluted solution for each dosage unit, thus leading to a higher level of
convenience for the storage and usage of atropine sulfate. The Group believes OT-101-S will solve the instability of atropine sulfate solutions under physiological (neutral) pH conditions and thus become a reliable treatment method for myopia in children.